KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

RANTAG 300 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

300 MG

 

GENERIC NAME:

RANITIDINE

 

MANUFACTURER:

JULPHAR

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Esophagitis, erosive

Gastroesophageal Reflux Disease

Mastocytosis, systemic

Ulcer, duodenal

Ulcer, gastric

Zollinger- Ellison syndrome

 

SIDE EFFECTS:

abdominal pain

agitation

agranulocytosis

alopecia

anaphylactoid reactions

angioedema

aplastic anemia

arthralgia

AV block

blurred vision

bronchospasm

confusion

constipation

delirium

depression

diarrhea

dizziness

elevated hepatic enzymes

eosinophilia

erythema multiforme

gynecomastia

hallucinations

headache

hemolytic anemia

hepatitis

impotence

insomnia

jaundice

leukopenia

libido decrease

maculopapular rash

myalgia

nausea/vomiting

neutropenia

pancreatitis

pancytopenia

paranoia

premature ventricular contractions (PVCs)

sinus bradycardia

sinus tachycardia

Stevens-Johnson syndrome

thrombocytopenia

toxic epidermal necrolysis

vasculitis

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

breast-feeding

children

elderly

gastric cancer

2-blocker*hypersensitivity#243"H2-blocker hypersensitivity

infants

infection

neonatal prematurity

neonates

phenylketonuria

porphyria

pregnancy

renal disease

renal failure

renal impairment

 

ADULT DOSE:

Duodenal ulcer-Treatment: Oral, 150 mg two times a day or 300 mg at bedtime. Prophylaxis of recurrent duodenal ulcer: Oral, 150 mg at bedtime. Gastric ulcer, benign, active-Treatment: Oral, 150 mg two times a day. Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 75 mg at onset of symptoms; dose may be repeated once in twenty-four hours. Prophylaxis: Oral, 75 mg thirty to sixty minutes before consuming food or beverages expected to cause symptoms. Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 150 mg two times a day, the dosage being adjusted as needed and therapy continued as long as clinically indicated. Doses up to 6 grams per day have been used in severe cases. Gastroesophageal reflux-Oral, 150 mg two times a day. Note: The recommended oral dose for erosive esophagitis is 150 mg four times a day. Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Oral, 150 mg every twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Reductions in dosage may also be required if hepatic function impairment is present.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Duodenal ulcer or Gastric ulcer-Oral, 2 to 4 mg per kg of body weight, two times a day up to a maximum dose of 300 mg per day. Gastroesophageal reflux-Oral, 2 to 8 mg per kg of body weight per dose three times a day. Note: In certain circumstances, doses may be titrated based on gastric pH. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Duodenal ulcer-Treatment: Oral, 150 mg two times a day or 300 mg at bedtime. Prophylaxis of recurrent duodenal ulcer: Oral, 150 mg at bedtime. Gastric ulcer, benign, active-Treatment: Oral, 150 mg two times a day. Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 75 mg at onset of symptoms; dose may be repeated once in twenty-four hours. Prophylaxis: Oral, 75 mg thirty to sixty minutes before consuming food or beverages expected to cause symptoms. Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 150 mg two times a day, the dosage being adjusted as needed and therapy continued as long as clinically indicated. Doses up to 6 grams per day have been used in severe cases. Gastroesophageal reflux-Oral, 150 mg two times a day. Note: The recommended oral dose for erosive esophagitis is 150 mg four times a day. Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Oral, 150 mg every twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Reductions in dosage may also be required if hepatic function impairment is present.

 

 

PREVIOUS

  

NEXT